Research graph
References from Real-World Outcomes of [ 177 Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
10.1016/s1470-2045(23)00529-6
10.1016/s1470-2045(23)00529-6 · External reference
French AFU Cancer Committee Guidelines–update 2024–2026: prostate cancer–management of metastatic disease and castration resistance
10.1016/j.fjurol.2024.102710 · 2024 · External reference
10.1007/s00259-023-06255-8
10.1007/s00259-023-06255-8 · External reference
10.1016/j.annonc.2020.06.011
10.1016/j.annonc.2020.06.011 · External reference
Advanced and metastatic prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2026.01.015 · 2026 · External reference
PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment [abstract]
10.1200/jco.2024.42.4_suppl.157 · 2024 · External reference
10.1016/j.ejca.2014.03.015
10.1016/j.ejca.2014.03.015 · External reference
Frequency and prognostic significance of the PSA flare-up phenomenon in men with castration-resistant prostate cancer undergoing docetaxel-based chemotherapy [abstract]
10.1200/jco.2012.30.5_suppl.92 · 2012 · External reference
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
10.1177/1758835920987654 · 2021 · External reference
Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan ([177Lu]Lu-PSMA-617): a real-world US study [abstract]
10.1200/jco.2024.42.4_suppl.81 · 2024 · External reference
10.2967/jnumed.124.267816
10.2967/jnumed.124.267816 · External reference
10.2967/jnumed.116.183194
10.2967/jnumed.116.183194 · External reference
10.1016/s0140-6736(24)01653-2
10.1016/s0140-6736(24)01653-2 · External reference
10.1016/j.annonc.2025.09.101
10.1016/j.annonc.2025.09.101 · External reference
10.1016/s1470-2045(25)00009-9
10.1016/s1470-2045(25)00009-9 · External reference
Efficacy of [177Lu]Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis [abstract]
10.1200/jco.2025.43.5_suppl.121 · 2025 · External reference
Unresolved reference
External reference
